Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk:
Evidence, guideline evolution, and questions to be resolved

June 2009
This supplement was supported by Boehringer Ingelheim Pharmaceuticals, Inc and was submitted by the Primary Care Education Consortium.

Management of hypertension is particularly important for primary care practitioners who must incorporate new options into therapeutic regimens and make treatment decisions based on the best clinical evidence. This supplement focuses on the renin-angiotensin aldosterone system (RAAS), its role in cardiovascular and renal disease, and therapies that modulate actions of the RAAS.

Full text | PDF 

Online-only: Table 1